S

Sangamo Therapeutics, Inc. Common Stock

XNAS · Laboratory Analytical Instruments · S&P 500

$0.14

-$0.01 (-6.44%) today

Open $0.15 High $0.15 Low $0.13 Vol 5,051K Avg $0.14

Related Stocks

Find similar stocks by technical condition — S&P 500 universe

Symbol Company Name Exchange Currency Category
LIMN Liminatus Pharma, Inc. Class A Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CMPX Compass Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
EXOZ eXoZymes Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PHGE BiomX Inc. XASE USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SANA Sana Biotechnology, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SGMO Sangamo Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PCVX Vaxcyte, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
TECH Bio-Techne Corp. XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CELZ Creative Medical Technology Holdings, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
MGTX MeiraGTx Holdings plc Ordinary Shares XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

52-week price range

$0.00 $0.00

Price is 0.0% above its 52-week low and 0.0% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.

  • Primary Exchange: XNAS
  • Market Cap: 86997543.57
  • Address:
  • Category: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
  • Total Employees: 142
  • Listing Date: 2000-04-06